Tiotropium in the management of paediatric and adolescent asthma: Systematic review

Paediatr Respir Rev. 2021 Jun;38:58-62. doi: 10.1016/j.prrv.2020.08.003. Epub 2020 Aug 25.

Abstract

Tiotropium bromide is a long-acting muscarinic antagonist (LAMA) and is the only LAMA licensed for management for patients' ≥6 years old with severe asthma who have experienced one or more severe asthma exacerbations in the preceding year. Recent clinical trials have demonstrated that once-daily tiotropium is safe and efficacious in 6-17 year-olds with symptomatic asthma despite treatment with inhaled corticosteroids (ICSs), with or without additional controllers. In this paper, we review the evidence of the safety and efficacy of tiotropium add-on maintenance treatment in children and adolescents with symptomatic moderate and severe asthma.

Keywords: Asthma; Children; Efficacy; Safety; Tiotropium.

Publication types

  • Review
  • Systematic Review

MeSH terms

  • Administration, Inhalation
  • Adolescent
  • Adrenal Cortex Hormones / therapeutic use
  • Asthma* / drug therapy
  • Bronchodilator Agents / therapeutic use
  • Child
  • Humans
  • Muscarinic Antagonists / therapeutic use
  • Tiotropium Bromide / therapeutic use

Substances

  • Adrenal Cortex Hormones
  • Bronchodilator Agents
  • Muscarinic Antagonists
  • Tiotropium Bromide